[go: up one dir, main page]

MA47408A - CANCER TREATMENT - Google Patents

CANCER TREATMENT

Info

Publication number
MA47408A
MA47408A MA047408A MA47408A MA47408A MA 47408 A MA47408 A MA 47408A MA 047408 A MA047408 A MA 047408A MA 47408 A MA47408 A MA 47408A MA 47408 A MA47408 A MA 47408A
Authority
MA
Morocco
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
MA047408A
Other languages
French (fr)
Other versions
MA47408B1 (en
Inventor
Anjali Narayan Avadhani
Porre Peter Marie Z De
Yohann Loriot
Ruixo Juan Jose Perez
Arlene O Siefker-Radtke
Kim Stuyckens
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47408A publication Critical patent/MA47408A/en
Publication of MA47408B1 publication Critical patent/MA47408B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA47408A 2017-12-20 2018-02-02 CANCER TREATMENT MA47408B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (2)

Publication Number Publication Date
MA47408A true MA47408A (en) 2019-12-11
MA47408B1 MA47408B1 (en) 2023-08-31

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47408A MA47408B1 (en) 2017-12-20 2018-02-02 CANCER TREATMENT

Country Status (5)

Country Link
EA (1) EA201991818A1 (en)
MA (1) MA47408B1 (en)
PT (1) PT3576740T (en)
TW (1) TWI798199B (en)
WO (1) WO2018141921A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12133851B2 (en) * 2018-09-21 2024-11-05 Janssen Pharmaceutica Nv Treatment of cholangiocarcinoma
US12180207B2 (en) 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
CA3126959A1 (en) * 2019-02-12 2020-08-20 Janssen Pharmaceutica Nv Cancer treatment
CA3133348A1 (en) * 2019-03-15 2020-09-24 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
JOP20210266A1 (en) * 2019-03-29 2023-01-30 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
WO2020201138A1 (en) * 2019-03-29 2020-10-08 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CA3141871A1 (en) * 2019-05-31 2020-12-03 Qed Therapeutics, Inc. Methods of treating urinary system cancers
WO2021119108A1 (en) * 2019-12-09 2021-06-17 Cedars-Sinai Medical Center Use of fgfr inhibitors for treatment of idiopathic short stature
BR112022015827A2 (en) * 2020-02-12 2022-10-04 Janssen Pharmaceutica Nv FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HIGH RISK INVASIVE NON-MUSCULAR BLADDER CANCER
MX2022009904A (en) * 2020-02-12 2022-08-25 Janssen Pharmaceutica Nv FGFR TYROSINE KINASE INHIBITORS AND ANTI-PD1 AGENTS FOR THE TREATMENT OF UROTHELIAL CARCINOMA.
CA3195543A1 (en) * 2020-09-17 2022-03-24 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating adenoid cystic carcinoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (en) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Also Published As

Publication number Publication date
MA47408B1 (en) 2023-08-31
WO2018141921A1 (en) 2018-08-09
EA201991818A1 (en) 2020-02-05
PT3576740T (en) 2023-08-18
TWI798199B (en) 2023-04-11
TW201839399A (en) 2018-11-01

Similar Documents

Publication Publication Date Title
EP3488001A4 (en) TREATMENT OF CANCER
MA49144A (en) POLYTHERAPIES FOR THE TREATMENT OF CANCER
IL255261A0 (en) Cancer treatment methods
MA47501A (en) CYCLIC DI-NUCLEOTID DERIVATIVE FOR CANCER TREATMENT
MA47408A (en) CANCER TREATMENT
EP3388004A4 (en) TREATMENT INSTRUMENT
PL3283527T3 (en) COMBINED TREATMENT OF CANCER
EP3621592A4 (en) POLYTHERAPIES FOR CANCER TREATMENT
MA50409A (en) POLYTHERAPIES FOR THE TREATMENT OF CANCER
EP3432888A4 (en) TREATMENT OF CANCER WITH TG02
MA41555A (en) POLYTHERAPY FOR CANCER TREATMENT
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
EP3606531A4 (en) CANCER TREATMENT METHODS
EP3474854A4 (en) CANCER TREATMENT COMBINATIONS
MA45429A (en) POLYTHERAPY FOR CANCER TREATMENT
EP3389645A4 (en) COMBINATIONS FOR THE TREATMENT OF CANCER
PT3622953T (en) COMBINED TREATMENT OF CANCER
MA52627A (en) CANCER TREATMENT
EP3375108A4 (en) DEWLAN TREATMENT
EP3359255A4 (en) POLYTHERAPIES FOR THE TREATMENT OF CANCER
MA46361A (en) TREATMENT OF PROSTATE CANCER
EP3733175A4 (en) CANCER TREATMENT
IL268463A (en) Cancer treatment
EP3610026A4 (en) BLADDER CANCER TREATMENT METHODS
EP3546020C0 (en) CANCER TREATMENT DEVICE